Relgin 0.5 mg (Rasagiline)

Product Overview

Relgin 0.5 mg is a prescription medication formulated for the management of Parkinson’s disease. It contains the active ingredient rasagiline, a selective monoamine oxidase‑B (MAO‑B) inhibitor that helps preserve dopamine levels in the brain. Manufactured by Intas Pharmaceuticals Ltd, each strip contains ten tablets, and the product is available in pack sizes of 30, 60, or 90 tablets to suit individual treatment plans. The 0.5 mg strength provides a balanced pharmacokinetic profile suitable for once‑daily dosing, and the tablet formulation ensures consistent bioavailability. The medication is intended for oral administration and should be taken exactly as directed by a healthcare professional. For more detailed prescribing information, see the official FDA label FDA prescribing information. Additional scientific context can be found on the NIH bookshelf and on Drugs.com.

What is Relgin 0.5 mg (Rasagiline)

Relgin 0.5 mg is the branded version of rasagiline mesylate, a small‑molecule drug that selectively blocks the enzyme MAO‑B. By inhibiting MAO‑B, rasagiline reduces the metabolic breakdown of dopamine, thereby increasing dopamine availability in the nigrostriatal pathway. This mechanism is distinct from levodopa or dopamine agonists, as it does not directly stimulate dopamine receptors but rather protects existing dopamine from degradation. The 0.5 mg dose is the standard starting strength for most adults initiating therapy for Parkinson’s disease. Clinically, rasagiline is classified as a disease‑modifying agent because it may slow the progression of motor symptoms when used early in the disease course. The drug is listed in the MedlinePlus database and is recognized by the World Health Organization’s Essential Medicines List. Early use may also reduce the cumulative dose of levodopa required later in disease progression.

Uses and Benefits

The primary therapeutic use of Relgin 0.5 mg is to improve motor function in patients with early‑to‑mid stage Parkinson’s disease, either as monotherapy or as an adjunct to levodopa. Clinical trials have demonstrated modest improvements in UPDRS scores, reduced “off” time, and a lower incidence of dyskinesia compared with placebo. In addition, rasagiline’s once‑daily dosing improves adherence, which is a critical factor in chronic neurologic therapy. Patients often report smoother motor transitions and a decreased need for rescue medication. From a commercial perspective, Relgin is positioned as a cost‑effective alternative to newer MAO‑B inhibitors, offering comparable efficacy with a well‑characterized safety profile. Real‑world evidence from post‑marketing surveillance indicates that many users experience sustained symptom control over periods of up to two years.

How It Works

Rasagiline’s pharmacological action hinges on its irreversible inhibition of MAO‑B, an enzyme predominantly expressed in presynaptic terminals of dopaminergic neurons. When MAO‑B is blocked, the oxidative deamination of dopamine is slowed, leading to higher intracellular dopamine concentrations. This effect is dose‑dependent and persists until new enzyme synthesis replaces the inhibited population. Unlike reversible MAO inhibitors, rasagiline does not significantly affect tyramine metabolism, which reduces the risk of hypertensive crises associated with dietary tyramine intake. The drug’s pharmacokinetic profile includes rapid absorption, high plasma protein binding, and elimination primarily via hepatic metabolism. Its half‑life of approximately 17 hours supports once‑daily dosing and contributes to steady‑state concentrations that are maintained with minimal peak‑trough fluctuations. The irreversible binding leads to a duration of action that can extend beyond the dosing interval, contributing to steady motor control throughout the day.

Dosage Guidelines

For adults newly diagnosed with Parkinson’s disease, the recommended initial dose of Relgin 0.5 mg is one tablet taken once daily, preferably in the morning, with or without food. After at least six weeks, the dose may be increased to 1 mg per day (two tablets) if the response is insufficient and tolerability is confirmed. Dose adjustments are generally not required for renal impairment, but patients with severe hepatic disease should be monitored. Missed doses should be taken as soon as remembered unless it is close to the next scheduled dose; otherwise, skip the missed dose and continue with the regular schedule. Consistent daily timing helps maintain stable plasma levels. The tablets are supplied in strips of ten, and pack sizes of 30, 60, or 90 tablets can be selected based on treatment length. Store at room temperature, away from moisture and heat. For full prescribing information, see the DailyMed label archive. Elderly patients may start at the lower dose and be titrated more cautiously.

Side Effects

Most patients tolerate Relgin 0.5 mg well, but it can cause adverse reactions. Common side effects include headache, dizziness, fatigue, and mild gastrointestinal discomfort. Less common events are orthostatic hypotension, insomnia, and, rarely, hallucinations or confusion, especially in older adults with dementia. Patients may also experience vivid dreams, which usually resolve with continued therapy. Serious events such as severe liver enzyme elevations are uncommon but have been reported. Report any new or worsening psychiatric symptoms, muscle pain, or signs of an allergic reaction (rash, swelling, breathing difficulty) to a healthcare provider promptly. For a full safety profile, consult the FDA’s medication safety resources.

Warnings and Precautions

Relgin 0.5 mg should be prescribed with caution in patients with a history of severe cardiovascular disease, uncontrolled hypertension, or psychiatric disorders such as psychosis. Concomitant use of other MAO‑B inhibitors, certain antidepressants, or opioids may increase the risk of serotonin syndrome or additive hypotensive effects. Alcohol consumption should be limited, as it may exacerbate dizziness or orthostatic symptoms. Pregnant or breastfeeding women should avoid this medication unless the benefits clearly outweigh the risks, as animal studies have shown potential fetal toxicity. Healthcare providers should perform baseline liver function tests before initiating therapy and repeat them periodically during treatment. Caution is advised in patients with a history of melanoma, as rare cases of skin reactions have been reported. Finally, abrupt discontinuation is generally not necessary, but patients should not stop the medication without consulting their physician, particularly if they have been on therapy for an extended period.

Frequently Asked Questions

1. Can Relgin 0.5 mg be taken with food? Yes, the tablet can be taken with or without food. However, taking it at the same time each day helps maintain consistent drug levels and supports steady plasma concentrations.
2. Is Relgin 0.5 mg suitable for patients with advanced Parkinson’s disease? It may be used as an adjunct in later stages, but efficacy can diminish as disease progresses. Physicians often consider other therapeutic options based on individual response and may combine it with other agents for optimal control.
3. How does Relgin differ from levodopa? Relgin works by preserving dopamine rather than supplying it directly. This distinguishes its mechanism of action and may reduce the incidence of levodopa‑induced motor fluctuations and dyskinesia.
4. What should I do if I miss a dose? Take the missed dose as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume your regular schedule; do not double up. Maintaining a consistent dosing schedule is important for sustained therapeutic effect.
5. Are there any dietary restrictions while on Relgin? No specific dietary restrictions are required, but patients should avoid excessive alcohol and be cautious with medications that may interact with MAO‑B inhibition, such as certain antidepressants or opioids.

Related Products

• Potassium Citrate 5 mg (Generic)
• Syncapone 100 mg (Levodopa/Carbidopa/Entacapone)
• Axpero 5 Mg (Axitinib)
• Glycolate 1 mg Tablet (Glycopyrrolate)
• Morr-F 3 (Minoxidil/Finasteride)
• Adapen Gel (Adapalene)
• Intacaine 2% Gel 30g (Lidocaine)
• Acamptas 333 mg (Acamprosate)
• Naltima 50 mg (Naltrexone)
• Itaspor 100 mg (Itraconazole)
• C-NAC Eye Drop (Sodium Carboxymethylcellulose/N-Acetyl-Carnosine)
• Lashisma Solution 3 ml (Bimatoprost)